双胎妊娠中母体血浆游离胎儿DNA分析作为21、18和13三体筛查试验
本研究评估了双胎妊娠中游离胎儿DNA(cfDNA)筛查三种常染色体三体的效用。492例超声无异常的双胎妊娠前瞻性收集数据并回顾性分析,cfDNA首次检测失败率2.9%,仅母体体重为失败独立预测因素,21三体特异性99.8%(95% CI,98.7-100.0%),结论认为cfDNA可作为一线或二线筛查试验。
要点
- 双胎妊娠cfDNA首次检测失败率为2.9%(12/420),仅母体体重为失败独立预测因素。
- cfDNA检出全部3例21三体和唯一1例18三体,21三体特异性99.8%(95% CI,98.7-100.0%)。
- 自然受孕与辅助生殖技术受孕组间母体体重及cfDNA无结果率无显著差异。
核心结论
- 在超声无异常的双胎妊娠中,cfDNA筛查21、18和13三体具有高成功率和良好性能,因此常规实践中cfDNA分析可考虑作为一线或二线筛查试验。
研究设计与样本
- 前瞻性收集数据并回顾性分析,共纳入492例超声无异常的双胎妊娠,cfDNA检测作为一线筛查或常规血清筛查后检测,采用大规模平行测序,胎儿分数阈值8%。
主要发现
- 377例在一线筛查(早孕期超声后)接受cfDNA分析,115例在血清筛查后接受。
- 420例有结局且评估cfDNA筛查的妊娠中,78.7%为双绒毛膜双羊膜囊。
- 12例(2.9%)首次检测失败,回归分析显示仅母体体重为检测失败的显著独立预测因素。
- 10例获取第二份样本后均获得结果。
- cfDNA分析检出全部3例21三体和唯一1例18三体。
关键数值与推荐
- cfDNA检测评估所用胎儿分数阈值为8%。
- 21三体特异性99.8%(95% CI,98.7-100.0%)。
临床怎么用
- 作者认为,在超声无异常的双胎妊娠常规实践中,cfDNA分析可考虑作为一线或二线筛查试验。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate in twin pregnancy the utility of non-invasive prenatal testing using circulating cell-free fetal DNA (cfDNA) in screening for the three main autosomal fetal trisomies. METHODS: cfDNA testing was offered to 492 patients with a twin pregnancy without ultrasound anomaly as a first-line screening test or after routine serum screening. Data were collected prospectively and a retrospective analysis was performed. cfDNA analysis was performed by massively parallel sequencing. The fetal-fraction threshold used for test evaluation was 8%. Regression analysis was performed to investigate the effect on the test failure rate of maternal and pregnancy characteristics, and the performance of the test was also reported. RESULTS: cfDNA analysis was performed as a first-line test (after the first-trimester scan) in 377 patients and following serum screening in 115. Of the 420 pregnancies for which outcome was available and cfDNA screening was assessed, 78.7% were dichorionic-diamniotic. The test failed on the first attempt in 12 (2.9%) pregnancies, and regression analysis demonstrated that only maternal weight was a significant independent predictor of test failure. A result was subsequently achieved in the 10 cases for which a second sample was obtained. cfDNA analysis identified all three cases of trisomy 21 and the only case of trisomy 18. For trisomy 21, the specificity was 99.8% (95% CI, 98.7-100.0%). When considering pregnancies according to whether they were conceived spontaneously or after assisted reproductive technology, there were no significant differences in terms of maternal weight or no-result rate for cfDNA screening between these two groups. CONCLUSIONS: In twin pregnancy without fetal ultrasound abnormality, cfDNA screening for trisomies 21, 18 and 13 had a high success rate and good performance. Therefore, in routine practice, cfDNA analysis could be considered as a first- or second-line screening test. Copyright © 2017 ISUOG. Published by John Wiley & Sons Ltd.
引用
- Le Conte G, Letourneau A, Jani J, et al. Cell-free fetal DNA analysis in maternal plasma as screening test for trisomies 21, 18 and 13 in twin pregnancy. Ultrasound Obstet Gynecol. 2018. PMID: 28833712. doi:10.1002/uog.18838
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。